Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
AstraZeneca Mexican National Institute of Public Health |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00262548 |
The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: Rosuvastatin; improvement of lipid profile |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women |
Estimated Enrollment: | 100 |
Study Start Date: | October 2005 |
Ages Eligible for Study: | 45 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Mexico, Morelos | |
Research site | |
Cuernavaca, Morelos, Mexico |
Study Director: | Astra Zeneca Mexico Medical Director, MD | AstraZeneca |
Principal Investigator: | Simón Barquera Cervera, MD | Mexican National Institute of Public Health |
Study ID Numbers: | DM-CRESTOR-0001, D3560L00018 |
Study First Received: | October 26, 2005 |
Last Updated: | August 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00262548 |
Health Authority: | Mexico: Federal Commission for Protection Against Health Risks |
Obesity Menopause |
Obesity Rosuvastatin Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Menopause |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |